Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHumanigen Inc

Humanigen Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2024-04-09T03:57:33.433640Z
Market Cap
0.10M

Momentum Score

…

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.00
Low
0.24
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
1.70M
Revenue Per Share
0.02
Gross Profit TTM
-209.52M
Debt / Equity
-1.06
ROE
-2165.43%
Net Debt
-10.15M
ROCE
151.79%
Diluted EPS TTM
-0.51

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -70.73M -236.65M -89.53M -10.29M -12.00M
Net income -70.24M -238.91M -90.87M -11.64M -12.00M
Selling general administrative 15.61M 23.25M 15.80M 6.33M 9.11M
Gross profit 2.51M 3.60M 0.31M -2.15M -1.77M
Reconciled depreciation - - - 0.00M 0.02M
Ebit -68.30M -232.77M -88.20M -8.94M -11.01M
Ebitda -67.81M -234.38M -88.20M -8.95M -10.99M
Depreciation and amortization 0.49M -1.61M -0.00M -0.00M 0.02M
Non operating income net other - -1.61M -0.00M -0.00M 0.18M
Operating income -68.30M -232.77M -88.20M -8.94M -11.33M
Other operating expenses 70.82M 236.37M 88.51M 8.94M 11.33M
Interest expense 2.92M 2.26M 1.34M 1.35M 0.85M
Net interest income -2.92M -2.26M -1.34M -1.35M -0.85M
Income tax expense -0.49M 2.26M 1.34M 1.35M 0.18M
Total revenue 2.51M 3.60M 0.31M 0.00M 0.00M
Total operating expenses 70.82M 236.37M 88.51M 8.94M 11.33M
Cost of revenue - - - 2.15M 1.77M
Total other income expense net -2.43M -3.88M -1.34M -1.35M 0.18M
Net income from continuing ops -70.73M -236.65M -89.53M -10.29M -12.00M
Net income applicable to common shares - -236.65M -89.53M -10.29M -12.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 11.20M 71.06M 68.30M 0.52M 1.37M
Intangible assets - - 0.02M - -
Other current assets 0.95M 0.95M 0.47M 0.31M 0.48M
Total liab 57.96M 94.75M 22.76M 14.84M 9.48M
Total stockholder equity -46.77M -23.69M 45.55M -14.32M -8.11M
Deferred long term liab - 1.02M 2.34M - -
Other current liab 14.79M 19.88M 5.46M 3.31M 3.13M
Common stock 0.12M 0.06M 0.05M 0.11M 0.11M
Capital stock 0.12M 0.06M 0.05M 0.11M 0.11M
Retained earnings -681.81M -611.08M -374.43M -284.89M -274.60M
Other liab - 1.02M 2.34M - -
Other assets - 0.09M 0.07M 0.07M 0.07M
Cash 10.15M 70.02M 67.74M 0.14M 0.81M
Total current liabilities 56.19M 68.72M 20.41M 13.59M 8.26M
Current deferred revenue 0.88M 4.14M 1.87M - -
Net debt -10.15M -45.01M -67.74M 6.34M 2.68M
Short term debt - - 5.24M 5.24M 2.28M
Short long term debt - - - 5.24M 2.28M
Short long term debt total - 25.01M - 6.49M 3.50M
Other stockholder equity 634.92M 587.33M 419.92M 270.46M 266.38M
Total current assets 11.11M 70.97M 68.21M 0.45M 1.30M
Net tangible assets - -23.69M 45.52M -14.32M -8.11M
Long term debt - 25.01M - 1.25M 1.22M
Accounts payable 40.52M 44.70M 13.08M 5.05M 2.86M
Common stock total equity - 0.06M 0.05M 0.11M 0.11M
Retained earnings total equity - -611.08M -374.43M -284.89M -274.60M
Non currrent assets other 0.09M 0.09M 0.07M 0.07M 0.07M
Non current assets total 0.09M 0.09M 0.09M 0.07M 0.07M
Long term debt total - 25.01M - 1.25M 1.22M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - 0.00M -0.02M - -
Change to liabilities - 30.28M 17.36M 2.58M -0.07M
Total cashflows from investing activities - - -0.02M -0.02M -0.02M
Net borrowings - 24.44M -0.83M 2.82M 3.48M
Total cash from financing activities 16.84M 186.32M 137.47M 3.33M 6.26M
Change to operating activities - 16.39M 9.16M 0.56M 0.45M
Net income -70.73M -236.65M -89.53M -10.29M -12.00M
Change in cash -59.86M 2.28M 67.59M -0.67M 0.05M
Begin period cash flow 70.02M 67.74M 0.21M 0.89M 0.84M
End period cash flow 10.15M 70.02M 67.81M 0.21M 0.89M
Total cash from operating activities -76.70M -184.04M -69.85M -4.00M -6.21M
Issuance of capital stock 41.84M 159.91M 139.76M 0.18M 2.78M
Depreciation - 0.56M - 1.29M 0.02M
Other cashflows from investing activities - - -0.02M - -
Sale purchase of stock - 161.88M 140.34M 0.51M 2.78M
Other cashflows from financing activities - 26.41M 1.48M 3.65M 3.48M
Change to netincome - 5.93M 2.11M 2.02M 4.54M
Capital expenditures 0.00M 0.00M 0.02M 0.00M 0.00M
Cash flows other operating - -0.48M 0.21M 0.40M 0.49M
Cash and cash equivalents changes - 2.28M 67.59M -0.67M 0.05M
Change in working capital -11.78M 46.67M 17.19M 2.75M 0.26M
Stock based compensation 5.81M 5.37M 2.11M 2.02M 4.81M
Other non cash items - 0.56M 0.38M 1.51M 0.98M
Free cash flow -76.70M -184.04M -69.87M -4.00M -6.21M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Humanigen Inc

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

830 Morris Turnpike, Short Hills, NJ, United States, 07078-2625

973 200 3100

https://www.humanigen.com

6

Name Title Year Born
Dr. Cameron Durrant M.D., MBA Chairman, CEO, Principal Financial & Accounting Officer 1960
Dr. Dale Chappell M.B.A., M.D., MBA Chief Scientific Officer & Director 1970
Mr. Robert Atwill M.B.A. Sr. VP and Head of Asia-Pacific Region & Bus. Devel. NA
Mr. Edward P. Jordan M.B.A. Chief Commercial Officer 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…